Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Exela Pharma Sciences LLC
WARNING LETTER
•Exela Pharma Sciences LLC•November 15, 2024

Exela Pharma Sciences LLC – FDA Warning Letter, Nov 15, 2024

Record Details

On July 2, 2025, the FDA issued a Warning Letter to Exela Pharma Sciences, LLC, following an inspection from November 4-15, 2024, at their Lenoir, NC drug manufacturing facility. The letter cites significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211) for finished pharmaceuticals, rendering their drug products adulterated under the FD&C Act.

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** The firm failed to thoroughly investigate unexplained discrepancies or failures. This includes invalidating failing growth promotion results for sterility testing media without adequate root cause analysis, impacting numerous drug products. Similarly, out-of-specification (OOS) results for sub-visible particulate matter in sodium bicarbonate injection were invalidated without proper investigation or corrective actions, despite identified human error. The firm's responses were deemed inadequate for lacking revised procedures, comprehensive reviews, and protocols for retrospective assessments. 2. **Incomplete Laboratory Records (21 CFR 211.194(a)):** The firm failed to accurately document microbiology testing results, and test results were not verified by a second person for accuracy. An FDA investigator observed miscounted environmental monitoring plates. The firm's response was inadequate as it did not address the misread counts or potential data integrity concerns from single-

Company
Exela Pharma Sciences LLC
Inspection date
November 15, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • F. Gail Bormel (F.)
View Company Profile

ID · 832d5d8c-294f-4c3e-9653-35170b74e857

Violation Codes10
21 CFR 211.19221 CFR 211.167(a)21 U.S.C. 331(k)21 CFR 210.1(b)21 CFR 21021 CFR 200.10(b)21 U.S.C. 356C(b)21 CFR 21121 CFR 211.166(a)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Exela Pharma Sciences LLC
  • 483 - 2024-11-04November 4, 2024
  • EIR - 2019-10-22October 22, 2019
  • EIR - 2019-07-18July 18, 2019
  • 483 - 2019-07-18July 18, 2019
  • WARNING_LETTER - 2019-07-18July 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Exela Pharma Sciences LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.